Profile

Rubius Therapeutics, Inc. (RUBY)

$0.0218

+0.00 (+3.32%)

Dr. Laurence A. Turka M.D.
Healthcare
Biotechnology
NASDAQ Global Select

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.